Loading....
The activities of the Let’s Talk Prostate Cancer (LTPC) Expert Group are funded by Astellas Pharma Inc., Amgen Inc and Pfizer Inc, which collectively contribute to and support the objectives of the Expert group.
Astellas Pharma Inc. have full and exclusive editorial control over the LTPC Website

INCIDENCE

Prostate cancer incidence in Austria is below the European average of 153.9 per 100,000 population, at a rate of 141.2 per 100,000.1 Like in many other countries, prostate cancer is the most common malignancy in men in Austria.2

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022)
2 Institute for Cancer Research, Medical University of Vienna. Molecular Epidemiology of Prostate Cancer. Accessible at http://krebsforschung.meduniwien.ac.at/en/research/research-focus/cellular-and-molecular-tumorbiology/andrea-gsur/research-projects/molecular-epidemiology-of-prostate-cancer/ (last accessed February 2022)

Estimated prostate cancer incidence 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

MORTALITY

Mortality rates for prostate cancer are again slightly below the EU27 average of 32.1 per 100,000 population, at a rate of 32 per 100,000.1 In Austria, however, only lung cancer exceeds prostate cancer in terms of cancer mortality.2

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022)

2 Institute for Cancer Research, Medical University of Vienna. Molecular Epidemiology of Prostate Cancer. Accessible at http://krebsforschung.meduniwien.ac.at/en/research/research-focus/cellular-and-molecular-tumorbiology/andrea-gsur/research-projects/molecular-epidemiology-of-prostate-cancer/ (last accessed February 2022)

Prostate cacner mortality 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

SURVIVAL

From 2010-2014, the 5-year survival rate for prostate cancer patients in Austria was 90.2%.1 For comparison, the 5-year net survival rate for neighbouring countries such as Czechia and Slovakia is 85.3% and 74.7% respectively, but is lower than countries like France and Germany.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Prostate cacner age-standardised 5-year net survival (%)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

NATIONAL POLICES

The 2014 National Cancer Framework Programme guides Austria’s cancer response. The National Cancer Framework Programme is regarded as a strategic expert paper with the status of a recommendation, which was drawn up on behalf of the Federal Ministry of Health and provides an overview of the most important fields in oncology for health policy.

In addition, the Austrian Society of Urology has adopted the prostate cancer early detection proposals currently being promoted by Europa Uomo and the European Association of Urology as a model for every European country. The proposals comprise an algorithm showing who should be given a PSA test, when, and how different groups should be followed up.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Europa Uomo. Austrian urologists adopt early detection formula. 2021. Accessible at https://www.europa-uomo.org/news/austrian-urologists-adopt-early-detection-formula/ (last accessed February 2022)

CLINICAL GUIDELINES

The Austrian clinical community follow the European Association of Urology clinical guidelines for prostate cancer. The recommended care pathway, includes patient access to*:

Review by a multidisciplinary team
Support from a specialist nurse
Holistic needs assessment
A tailored treatment plan
Nutrition and exercise advice
Psychological support
Regular care reviews

Legend:

Recommendation included

Recommendation not included

*For a detailed explanation of the different patient support categories included in this scorecard, please follow the link.

CANCER CARE

Access to Specialists

The number of urologists per citizen in Austria is relatively high, with 16,737 citizens to every 1 urologist.1 In Czechia, the situation is similar with 15,267 citizens per urologist2 and likewise in Germany with 13,947 citizens per urologist.3

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Society of Residents in Urology (ESRU). Austria. March 2018. Accessible at https://esru.eu/?q=austria (last accessed March 2022)
2 European Society of Residents in Urology (ESRU). Czech Republic. March 2018. Accessible at https://esru.eu/?q=czech-republic (last accessed March 2022)
3 European Society of Residents in Urology (ESRU). Germany. March 2018. Accessible at https://esru.eu/?q=germany (last accessed March 2022)

Cost of cancer

In 2018, the direct cost of cancer in Austria was €289 per person,1 higher than the European average of €154 per person.2 This is similar to Germany, which spends €308 per person.1 Whilst a number of factors contribute to improved outcomes for those affected by prostate cancer, studies have shown that those countries that invest more in cancer care tend to achieve better outcomes for patients.3

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
3 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7.

Cancer medicines spend

Austria spends the highest amount per capita on cancer medicines in the EU, at €108 per capita.1 At the other end of the scale, Greece and Estonia only spend €4 per capita.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Approximate number of inhabitats per urologist - 2018*

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.

European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx
(last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf
(last accessed March 2022)

Direct health cost of cancer per person - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Per capita cost of cancer medicines - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

ORGANISATIONS

Patient organisations

The main prostate cancer patient organisation in Austria is:

Selbsthilfe Prostatakrebs
https://www.prostatakrebse.at/

Reference Number: ONC_2021_0148_BE
Date of preparation: January 2022

Europe Digital Atlas